Headlimes
- Rentokil's (NYSE:RTO)shares fell by 20% after a trading update revealed lower-than-expected revenue growth in North America.
- The company's North American operations, which represent 60% of total revenue, missed guidance due to slower growth.
- The decline impacts Rentokil’s integration efforts following its $6.7 billion Terminix acquisition and growth strategy.
Shares of Rentokil Initial experienced a significant decline of 20% by early afternoon, as reported by S&P Global Market Intelligence. The drop followed the company's trading update, which indicated that organic revenue growth in North America for the latter half of 2024 would be approximately 1%This figure falls short of the previously forecasted range of 2% to 4%.
Despite the seemingly minor deviation from projections, the impact is substantial due to North America's critical role in Rentokil's overall performanceThis region contributes 60% to the company's total revenue and operating profitThe update is particularly concerning because Rentokil's North American operations are central to its strategic expansion, particularly after the $6.7 billion acquisition of Terminix in 2022.
The Terminix acquisition, which was nearly half the size of Rentokil's market capitalization, was intended to accelerate growth in North AmericaTo support this integration, Rentokil launched the Right Way 2 Growth planThis strategy focused on expanding the Terminix brand, generating new leads, retaining staff and clients, and seamlessly incorporating Terminix employees into Rentokil's frameworkThe recent update indicates that these integration efforts have faced challenges, impacting the company's growth trajectory.